Arrowhead Pharmaceuticals Inc (ARWR)
Pretax margin
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) (ttm) | US$ in thousands | -297,360 | -202,491 | -176,563 | -146,405 | -150,714 | -172,278 | -153,924 | -111,802 | -182,986 | -140,846 | -125,904 | -109,591 | -102,609 | -84,551 | -24,242 | 9,705 | 53,438 | 68,149 | 45,511 | 9,569 |
| Revenue (ttm) | US$ in thousands | 166,263 | 225,258 | 245,998 | 267,743 | 278,338 | 243,231 | 249,939 | 263,418 | 144,424 | 138,288 | 107,638 | 89,123 | 79,841 | 87,993 | 123,653 | 138,974 | 163,593 | 168,796 | 136,758 | 94,788 |
| Pretax margin | -178.85% | -89.89% | -71.77% | -54.68% | -54.15% | -70.83% | -61.58% | -42.44% | -126.70% | -101.85% | -116.97% | -122.97% | -128.52% | -96.09% | -19.60% | 6.98% | 32.67% | 40.37% | 33.28% | 10.10% |
December 31, 2023 calculation
Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $-297,360K ÷ $166,263K
= -178.85%
Arrowhead Pharmaceuticals Inc.'s pretax margin has shown significant fluctuations over the past eight quarters. The company experienced negative pretax margins in all quarters, with sharp declines in Q1 2024 and Q4 2023 at -166.93% and -85.78% respectively. The pretax margin reached its lowest point in Q1 2024, indicating that the company's expenses were significantly impacting its profitability before tax. Despite this, there was a slight improvement in Q3 2023 compared to the preceding quarters. Overall, Arrowhead Pharmaceuticals Inc. faces challenges in generating profits before taxes and may need to focus on cost management strategies to improve its financial performance.
Peer comparison
Dec 31, 2023